Patents Examined by Roy Teller
  • Patent number: 9745348
    Abstract: The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below wherein A1, v, A2, w, A3, x, y, A4, z, R1, R2 and R3 are as defined in the application; or a salt thereof. The invention further relates to use of the peptides as antibacterial agents, or antitumor agents, including the medical use of the peptide in treating infection and/or cancer, as well as their use as preservatives and antibacterial agents in other products, including personal care products such as skin topical treatments, cleansers, mouth washes, toothpastes, shampoo, body lotions and creams etc.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 29, 2017
    Assignee: The University of Manchester
    Inventors: Jian R. Lu, Xiubo Zhao, Fang Pan, Mohammed Yaseen
  • Patent number: 9700071
    Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 11, 2017
    Assignee: Axcella Health Inc.
    Inventors: Nathaniel W. Silver, Geoffrey von Maltzahn, Michael J. Hamill, David Arthur Berry
  • Patent number: 9700548
    Abstract: The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: July 11, 2017
    Assignee: REQUIS PHARMACEUTICALS INC.
    Inventors: Lars Jacob Stray Knutsen, Judi Lois Knutsen
  • Patent number: 9683017
    Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 20, 2017
    Assignee: UNIVERSITY TENNESSEE RESEARCH FOUNDATION
    Inventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
  • Patent number: 9662369
    Abstract: The present invention relates to the use of a casein hydrolysate as an antiherpetic agent. This casein hydrolysate has an application in both the treatment and the prevention of the reactivation of a latent infection by a herpesvirus, and is effective both orally and topically. It also relates to a pharmaceutical composition in the form of cream, gel, ointment or paste for topical administration that contains it.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: May 30, 2017
    Assignee: NTD Labs, S.L.
    Inventors: Guillermo López Zarco, Pere Adell Winkler
  • Patent number: 9650417
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 16, 2017
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler
  • Patent number: 9649352
    Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: May 16, 2017
    Assignees: THE MEDICINES COMPANY, ABBVIE INC.
    Inventors: Adel Rafai Far, Gopal Krishna, Min Ding, Sanjay R. Chemburkar, Carl M. Knable, James P. Petzel, Julie J. Pruyne, Douglas M. Reamer
  • Patent number: 9630993
    Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: April 25, 2017
    Assignee: NESTEC S.A.
    Inventor: Nicholas Chi-Kwan Ling
  • Patent number: 9624288
    Abstract: Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed. The use of these compositions and nanoparticles, such as for the treatment of pain, cystic fibrosis and asthma, is also disclosed.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: April 18, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Yan Xu, Pei Tang, Tommy Tillman
  • Patent number: 9617305
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 11, 2017
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian M. Cali
  • Patent number: 9611298
    Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: April 4, 2017
    Assignee: Axcella Health Inc.
    Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Michael Hamill, Rajeev Chillakuru, John F. Kramarczyk
  • Patent number: 9611291
    Abstract: Process for the separation of a biomolecule containing at least one cationic group from a liquid medium containing said biomolecule, which comprises the use of a tetraphenylborate (TPB) salt.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: April 4, 2017
    Assignee: CORDEN PHARMA BRUSSELS PC
    Inventors: Roland Callens, Laurent Jeannin
  • Patent number: 9611312
    Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: April 4, 2017
    Assignee: ELASTAGEN PTY. LIMITED
    Inventor: Jens Sommer-Knudsen
  • Patent number: 9585941
    Abstract: A composition with a polypeptide including amino acid sequence LKKTET or a conservative variant thereof, the composition further including a carrier for application to a surface of a body.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: March 7, 2017
    Assignee: REGENERX BIOPHARMACEUTICALS, INC.
    Inventors: David Crockford, Allan L. Goldstein
  • Patent number: 9554999
    Abstract: Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: January 31, 2017
    Assignee: Windtree Therapeutics, Inc.
    Inventors: Sergio Cesco-Cancian, Thomas Hoy, Edward H. Trappler, Michael S. Thomas
  • Patent number: 9556225
    Abstract: The invention provides a novel peptide, and derivatives thereof, which is stable in aqueous solution and which stimulates proliferation and survival of endothelial cells and/or fibroblasts. The present peptide can be used at least to promote the S phase of the cell cycle, to stimulate production of extracellular matrix proteins, to reduce apoptosis, to inhibit production of reactive oxygen species and/or to reduce or prevent damage to cell integrity or morphology under stress conditions of serum deprivation.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: January 31, 2017
    Assignee: UNIAO QUIMICA FARMACEUTICA NACIONAL S/A
    Inventor: Miguel Giudicissi-Filho
  • Patent number: 9539278
    Abstract: It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: January 10, 2017
    Assignee: N.V. Nutricia
    Inventor: Robert Johan Joseph Hageman
  • Patent number: 9539304
    Abstract: This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: January 10, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Nicholas F. LaRusso, Tetyana V. Masyuk, Melissa Muff-Luett
  • Patent number: 9527887
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: December 27, 2016
    Assignee: Ironwood Pharmaceutical, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian M. Cali
  • Patent number: 9518086
    Abstract: The present disclosure provides novel crystalline forms of a compound that acts as a ?-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a ?-arrestin effector and uses thereof.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: December 13, 2016
    Assignee: Trevena, Inc.
    Inventors: Ritesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan